First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment : vimarsana.com

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

Related Keywords

United States , American , Timothyd Henry , Christian Rommel , Rogerj Hajjar , Head Of Research , American Heart Association Scientific Sessions , York Heart Association , Bayer Ag , Asklepios Biopharmaceutical Inc , Steering Committee Member , Asklepios Biopharmaceutical , Inhibition Therapy , New York Heart Association , Principal Investigator , Steering Committee , Heart Failure Awareness Week , Scientific Chair , Executive Committee , Pharmaceuticals Division , Viralgen Vector Core , Six Minute Walk Test , Intracoronary Gene Therapy , Subjects With Non Ischemic , Accessed February , Treasure Island , Statpearls Publishing ,